Adjuvant and Salvage Radiation Therapy After Prostatectomy: American Society for Radiation Oncology/American Urological Association Guidelines
- Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas (United States)
- Division of Urology, University of Connecticut Health Center, Farmington, Connecticut (United States)
- Department of Radiation Oncology, Mayo Medical School, Rochester, Minnesota (United States)
- Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia (Canada)
- Department of Urology, University of Michigan, Ann Arbor, Michigan (United States)
- Department of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana (United States)
- Glickman Urological Kidney Institute, Cleveland Clinic, Cleveland, Ohio (United States)
- Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina (United States)
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri (United States)
- Department of Radiation Oncology, University of California, San Francisco, San Francisco, California (United States)
- Four Oaks, Inc (United States)
Purpose: The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials: A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed. Results: Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation. Conclusions: Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.
- OSTI ID:
- 22267822
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 86, Issue 5; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma